- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 19.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Genelux GAAP EPS of -$0.86 misses by $0.01 | 1 | Seeking Alpha | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 19.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | 621 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses... ► Artikel lesen | |
| 19.03. | GENELUX Corp - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.02. | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 4 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; Genelux's Olvi-Vec Shows Promise; Monte Rosa Therapeutics' MRT-8102 Advances | 564 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 3 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch | ||
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 214 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 189 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 0,841 | -1,87 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| REDHILL BIOPHARMA | 0,851 | +2,33 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| IMMUNIC | 0,992 | -0,80 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Medical Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Medical Conferences in April
09.04.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| ESPERION | 1,869 | +0,75 % | Esperion Therapeutics, Inc.: Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) | - Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,928 | +2,20 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| CYBIN | 4,450 | 0,00 % | Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer | Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company... ► Artikel lesen | |
| KYNTRA BIO | 5,900 | -0,84 % | KYNTRA BIO, INC. - 8-K, Current Report | ||
| KARYOPHARM | 6,700 | -2,19 % | Karyopharm Therapeutics Inc.: Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction | - While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS -
- SENTRY... ► Artikel lesen | |
| BIOLINERX | 1,700 | 0,00 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,980 | +1,12 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®... ► Artikel lesen | |
| EDESA BIOTECH | 4,960 | +5,08 % | Edesa Biotech, Inc.: Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study | Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 2,940 | 0,00 % | Can-Fite BioPharma Ltd.: Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 | Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a... ► Artikel lesen | |
| BRIACELL THERAPEUTICS | 3,820 | +4,37 % | BriaCell Therapeutics and BriaPro Therapeutics Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License | PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 4,550 | +0,44 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026... ► Artikel lesen | |
| CINGULATE | 5,770 | -3,19 % | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 | Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues... ► Artikel lesen |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.